Enlarge / Packaging for Wegovy, manufactured by Novo Nordisk, is seen in this illustration photo.Getty | Jakub Porzycki
With the debut of remarkably effective weight-loss drugs, America’s high obesity rate and its uniquely astronomical prescription drug pricing appear to be set on a catastrophic collision course—one that threatens to “bankrupt our entire health care system,” according to a new Senate report that modeled the economic impact of the drugs in different uptake scenarios.
If just half of the adults in the US with obesity start taking a new weight-loss drug, such as Wegovy, the collective cost would total an estimated $411
→ Continue reading at Ars Technica